Pipeline
We prioritize disease areas with clear immune involvement, high unmet clinical need, and where EVs offer a best-in-class biological advantage over traditional biomarker approaches.
Discovery
Validation
Regulatory Approval
Discovery
Validation
Regulatory Approval
Discovery
Validation
Regulatory Approval
Melanoma
IO Therapeutics
PD-L1 x CTLA-4
With dual checkpoint regimens now standard in melanoma, identifying patients who derive sufficient benefit from anti–PD-1 monotherapy enables more targeted therapeutic deployment, reducing toxicity risk while preserving durable clinical outcomes.
Melanoma
IO Therapeutics
PD-L1 x CTLA-4
With dual checkpoint regimens now standard in melanoma, identifying patients who derive sufficient benefit from anti–PD-1 monotherapy enables more targeted therapeutic deployment, reducing toxicity risk while preserving durable clinical outcomes.
Melanoma
IO Therapeutics
PD-L1 x CTLA-4
With dual checkpoint regimens now standard in melanoma, identifying patients who derive sufficient benefit from anti–PD-1 monotherapy enables more targeted therapeutic deployment, reducing toxicity risk while preserving durable clinical outcomes.
Non-Hodgkin Lymphoma
IO Therapeutics
PD-L1, CD20/CD3 bi-spec., CD19-CAR-T, CD79b-ADCs
In a setting where checkpoint blockade has shown limited single-agent activity, predictive stratification can delineate a responsive subset, guiding rational monotherapy use and informing combination strategies in biomarker-enriched populations.
Non-Hodgkin Lymphoma
IO Therapeutics
PD-L1, CD20/CD3 bi-spec., CD19-CAR-T, CD79b-ADCs
In a setting where checkpoint blockade has shown limited single-agent activity, predictive stratification can delineate a responsive subset, guiding rational monotherapy use and informing combination strategies in biomarker-enriched populations.
Non-Hodgkin Lymphoma
IO Therapeutics
PD-L1, CD20/CD3 bi-spec., CD19-CAR-T, CD79b-ADCs
In a setting where checkpoint blockade has shown limited single-agent activity, predictive stratification can delineate a responsive subset, guiding rational monotherapy use and informing combination strategies in biomarker-enriched populations.
Renal Cell Carcinoma
IO Therapeutics
PD-L1 x VEGF TKI
Immune-based combinations dominate frontline RCC, yet not all patients require intensified regimens. Our platform supports data-driven monotherapy selection to enhance patient safety and optimize clinical development efficiency.
Renal Cell Carcinoma
IO Therapeutics
PD-L1 x VEGF TKI
Immune-based combinations dominate frontline RCC, yet not all patients require intensified regimens. Our platform supports data-driven monotherapy selection to enhance patient safety and optimize clinical development efficiency.
Renal Cell Carcinoma
IO Therapeutics
PD-L1 x VEGF TKI
Immune-based combinations dominate frontline RCC, yet not all patients require intensified regimens. Our platform supports data-driven monotherapy selection to enhance patient safety and optimize clinical development efficiency.
Cervical Cancer
IO Therapeutics
PD-L1
In advanced cervical cancer, anti–PD-L1 immunotherapy has shown benefit, but only a subset of patients respond. EVIIVE’s EV-based assay aims to identify responders early, helping tailor treatment strategies and avoid ineffective therapy.
Cervical Cancer
IO Therapeutics
PD-L1
In advanced cervical cancer, anti–PD-L1 immunotherapy has shown benefit, but only a subset of patients respond. EVIIVE’s EV-based assay aims to identify responders early, helping tailor treatment strategies and avoid ineffective therapy.
Cervical Cancer
IO Therapeutics
PD-L1
In advanced cervical cancer, anti–PD-L1 immunotherapy has shown benefit, but only a subset of patients respond. EVIIVE’s EV-based assay aims to identify responders early, helping tailor treatment strategies and avoid ineffective therapy.
